Sriaroon Panida, Ballow Mark
Division of Allergy, Immunology, and Rheumatology, Department of Pediatrics, University of South Florida, 140 7th ave S, CRI 4008, St. Petersburg, FL, 33701, USA.
Clin Rev Allergy Immunol. 2016 Apr;50(2):252-72. doi: 10.1007/s12016-014-8444-9.
Eosinophils can regulate local and systemic inflammation, and their presence in higher numbers appears to play an important role in the pathology of various atopic and inflammatory diseases. Eosinophil maturation, recruitment, and survival depend on several cytokine regulators, including interleukin (IL)-5, IL-4, and IL-13 as well as growth factors such as GM-CSF. Over the last decade, the approach to treating eosinophilic diseases has changed greatly. A number of biologic modulators have been developed to target eosinophilic inflammatory pathways, and their usage has resulted in variable clinical improvement in the treatment of eosinophilic-associated conditions. Novel targeted therapies that are safe and effective for treating these disorders are being investigated. This review summarizes the clinical use of biologic agents that have been studied in clinical trials or approved for treating eosinophilic diseases.
嗜酸性粒细胞可调节局部和全身炎症，其数量增多似乎在各种特应性和炎症性疾病的病理过程中发挥重要作用。嗜酸性粒细胞的成熟、募集和存活依赖于多种细胞因子调节因子，包括白细胞介素（IL）-5、IL-4和IL-13以及诸如粒细胞-巨噬细胞集落刺激因子（GM-CSF）等生长因子。在过去十年中，嗜酸性粒细胞疾病的治疗方法发生了很大变化。已经开发了多种生物调节剂来靶向嗜酸性粒细胞炎症途径，并且它们的使用在嗜酸性粒细胞相关病症的治疗中带来了不同程度的临床改善。正在研究对治疗这些疾病安全有效的新型靶向疗法。本综述总结了已在临床试验中进行研究或已获批准用于治疗嗜酸性粒细胞疾病的生物制剂的临床应用。
